32
Participants
Start Date
March 2, 2022
Primary Completion Date
April 22, 2022
Study Completion Date
April 22, 2022
Fruquintinib
Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
Dabigatran Etexilate
Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
Rosuvastatin
Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
PPD Development, Austin
Lead Sponsor
Hutchmed
INDUSTRY